Compare LTC Properties Inc (LTC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Merck & Co., Inc. — how do they compare? LTC Properties Inc trades at $42.53 (market cap $2.27B), while Merck & Co., Inc. trades at $146.29 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 154.7× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.42%). Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Merck & Co., Inc. for 98 Days on average.
| LTC | MRK | |
|---|---|---|
Market Cap | $2.27B | $351.28B |
Volume | 574,171 | 7,969,665 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $156.43 |
52-Week Low | $33.98 | $82.49 |
Typical Hold Time | 88 Days | 98 Days |
Enterprise Value | $3.01B | $398.04B |
Dividend Yield | 5.42% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.46, up 1.55% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT demonstrates strong fundamentals with 61.72% gross margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, though cash flow trends show significant investing outflows. Analyst consensus targets $49.67 with 32% buy ratings amid balanced risk-reward outlook.
LTC presents a balanced opportunity with steady income from monthly dividends and demographic tailwinds in senior housing, offset by execution risks from rapid portfolio transformation and rising interest rate sensitivity. The stock trades at reasonable valuations (P/E 15.02) but faces headwinds from its SHOP transition strategy and macroeconomic pressures on REIT valuations.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
